Marko Mijic (München / DE), Corinna Wirner-Piotrowski (München / DE), Dr. Federica Montagnese (München / DE), Dr. Natalia García Angarita (München / DE), Dr. Kristina Gutschmidt (München / DE), PD Dr. Stephan Wenninger (München / DE), Prof. Peter Young (Bad Feilnbach / DE), Prof. Dr. med. Benedikt Schoser (München / DE)
Abstract-Text (inkl. Referenzen)
Purpose: The professionals in the field of neuromuscular disorders (NMD) are challenged to help patients by clarifying possibilities and getting the right decision by various assistive gait devices (AGDs). Especially in slow advancing NMDs retaining mobility and independence in activities of daily living have a significant role. To our knowledge, this is the first systematic review that evaluated benefit and tolerability of current AGD supporting lower limbs functions during activities of daily living for individuals with neuromuscular disorders. Methods: This systematic review was conducted by "The Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) statement 2020" (1). The study protocol was registered at the open science framework: doi.org/10.17605/OSF.IO/28M65 on 21. November 2022. The following databases were searched: Pubmed/MEDLINE®, Web of Science, Scopus, Embase, and MEDLINE (via EBSCO). The AGD were categorized in five groups: (I) orthosis, (II) end-effector devices, (III) exoskeletons, (V) neuromuscular electrical stimulation and (V) neuroprosthesis and neural prosthesis. Results: The final systematic search resulted 8922 records. Based on the titles and abstracts, 217 papers are included for full text reading. At this stage, we are applying the inclusion and exclusion criteria to obtain a final number of studies for the review.
References:
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ. 2021;372.